EMA accepts MAA for GW's Epidiolex

GW Pharmaceuticals plc (NASDAQ:GWPH) said EMA accepted for review an MAA for Epidiolex cannabidiol as an adjunctive treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. GW said it expects a decision from EMA in 1Q19.

Epidiolex is an oral liquid formulation of cannabidiol, a phytocannabinoid found in Cannabis sativa...